Dr. Constantin Tamvakopoulos studied Chemistry at the University of Chicago and then received a Ph.D. in Biochemistry from Brown University in 1992. He then joined the Pharmaceutical Industry in the United States with a career of over 14 years in Departments of Pharmacokinetics and Drug Metabolism. He was a Senior Research Chemist and a Research Fellow at Merck & Co for seven years.
He accepted a tenure track position at the Division of Pharmacology, Biomedical Research Foundation, Academy of Athens in 2004, where he is currently Director of Research, Researcher A at Professor level. His research revolves around the development of targeted drugs to treat cancer as well as generating novel mass spectrometric approaches with significance in biomedical research. Dr. Tamvakopoulos, has over 65 publications in peer-reviewed journals, has served as a member of the scientific advisory board of the national regulatory agency for new drug approvals (EOF), as a Chair of peer review panels on the Danish Research Council, and has been a PI in several grants related to his research interests. He is a co-inventor of a recently filled patent on the application of an anti-Myc compound for pancreatic cancer and instrumental in organizing the Clinical trials program of BRFAA.